Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Maria Lagerström-Fermér"'
Autor:
Vesa Anttila, Antti Saraste, Juhani Knuuti, Pekka Jaakkola, Marja Hedman, Sara Svedlund, Maria Lagerström-Fermér, Magnus Kjaer, Anders Jeppsson, Li-Ming Gan
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 464-472 (2020)
Therapeutic angiogenesis may improve outcomes in patients with coronary artery disease undergoing surgical revascularization. Angiogenic factors may promote blood vessel growth and regenerate regions of ischemic but viable myocardium. Previous clinic
Externí odkaz:
https://doaj.org/article/80fe2f628af64fa483828090e9dde74d
Autor:
Li-Ming Gan, Maria Lagerström-Fermér, Leif G. Carlsson, Cecilia Arfvidsson, Ann-Charlotte Egnell, Anna Rudvik, Magnus Kjaer, Anna Collén, James D. Thompson, John Joyal, Ligia Chialda, Thomas Koernicke, Rainard Fuhr, Kenneth R. Chien, Regina Fritsche-Danielson
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diab
Externí odkaz:
https://doaj.org/article/4edc38b69f3e4b73a58e9dddd556b69b
Autor:
Eva Prescott, John Pernow, Antti Saraste, Axel Åkerblom, Oskar Angerås, David Erlinge, Erik L. Grove, Marja Hedman, Lisette O. Jensen, Sara Svedlund, Magnus Kjaer, Maria Lagerström-Fermér, Li-Ming Gan
Publikováno v:
Contemporary Clinical Trials Communications, Vol 19, Iss , Pp 100629- (2020)
Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pa
Externí odkaz:
https://doaj.org/article/ce1152fccd1e41868c126f3a24d193a0
Autor:
Eva-Lotte Lindstedt, Carl Amilon, Hans Ericsson, David Han, Maria Heijer, Carl Whatling, Karin Nelander, Li-Ming Gan, Erik Michaëlsson, Maria Lagerström-Fermér, Muir Russell, M Kjaer
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 812-819 (2021)
Clinical and Translational Science
Clinical and Translational Science
We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single-blind, placebo-controlled study, following once-daily multiple ascending dosing to stead
Autor:
Antti Saraste, Pekka Jaakkola, M Kjaer, Sara Svedlund, Marja Hedman, Anders Jeppsson, Li-Ming Gan, Maria Lagerström-Fermér, Juhani Knuuti, Vesa Anttila
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 464-472 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Therapeutic angiogenesis may improve outcomes in patients with coronary artery disease undergoing surgical revascularization. Angiogenic factors may promote blood vessel growth and regenerate regions of ischemic but viable myocardium. Previous clinic
Autor:
M Kjaer, Maria Heijer, Maria Lagerström-Fermér, Muna Albayaty, Hans Ericsson, Eva-Lotte Lindstedt, Karin Nelander, Stanko Skrtic, Pablo Forte
Publikováno v:
Clinical Pharmacology in Drug Development
AZD5718 is a first‐in‐class small‐molecule anti‐inflammatory drug with the potential to reduce the residual risk of cardiovascular events after myocardial infarction in patients receiving lipid‐lowering statin therapy. Leukotrienes are pote
Autor:
Sara Svedlund, Petur Petursson, Maria Lagerström-Fermér, Jacob Odenstedt, Truls Råmunddal, David Erlinge, Oskar Angerås, Inger Haraldsson, Li-Ming Gan, Helena U. Westergren, Kristina Torngren, Elmir Omerovic, Björn Redfors, Per Albertsson
Publikováno v:
Vascular Health and Risk Management
Inger Haraldsson,1,2 Li-Ming Gan,1–3 Sara Svedlund,1,4 Kristina Torngren,5 Helena U Westergren,6 Björn Redfors,1,2 Maria Lagerström-Fermér,3 Oskar Angerås,1,2 Truls Råmunddal,1,2 Petur Petursson,1,2 Jacob Odenstedt,1,2 Per Albertsson,1,2 David
Autor:
Thomas Koernicke, Ann-Charlotte Egnell, Cecilia Arfvidsson, Regina Fritsche-Danielson, Ligia Chialda, Li-Ming Gan, James D. Thompson, Anna Rudvik, Leif Carlsson, Anna Collén, Rainard Fuhr, Maria Lagerström-Fermér, Kenneth R. Chien, M Kjaer, John L. Joyal
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
Nature Communications
Nature Communications
Chemically modified mRNA is an efficient, biocompatible modality for therapeutic protein expression. We report a first-time-in-human study of this modality, aiming to evaluate safety and potential therapeutic effects. Men with type 2 diabetes mellitu
Autor:
Hans Ericsson, M Kjaer, Maria Heijer, Erik Michaëlsson, Carl Whatling, Maria Lagerström-Fermér, Rainard Fuhr, Eva-Lotte Lindstedt, Li-Ming Gan, Karin Nelander
Publikováno v:
British Journal of Clinical Pharmacology
Aims Myeloperoxidase activity can contribute to impaired vascular endothelial function and fibrosis in chronic inflammation-related cardiovascular disease. Here, we investigated the safety, tolerability and pharmacokinetics of the myeloperoxidase inh
Autor:
David Erlinge, Marja Hedman, Lisette Okkels Jensen, Axel Åkerblom, Maria Lagerström-Fermér, John Pernow, Li-Ming Gan, Sara Svedlund, Erik Lerkevang Grove, Oskar Angerås, Eva Prescott, M Kjaer, Antti Saraste
Publikováno v:
Contemporary Clinical Trials Communications, Vol 19, Iss, Pp 100629-(2020)
Prescott, E, Pernow, J, Saraste, A, Åkerblom, A, Angerås, O, Erlinge, D, Grove, E L, Hedman, M, Jensen, L O, Svedlund, S, Kjaer, M, Lagerström-Fermér, M & Gan, L M 2020, ' Design and rationale of FLAVOUR : A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction ', Contemporary Clinical Trials Communications, vol. 19, 100629 . https://doi.org/10.1016/j.conctc.2020.100629
Contemporary Clinical Trials Communications
Prescott, E, Pernow, J, Saraste, A, Åkerblom, A, Angerås, O, Erlinge, D, Grove, E L, Hedman, M, Jensen, L O, Svedlund, S, Kjaer, M, Lagerström-Fermér, M & Gan, L M 2020, ' Design and rationale of FLAVOUR : A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction ', Contemporary Clinical Trials Communications, vol. 19, 100629 . https://doi.org/10.1016/j.conctc.2020.100629
Contemporary Clinical Trials Communications
Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pa